Cryopreservation (Cell Cryopreservation)

Quick Answer

Cryopreservation is the cooling and storing of cells, tissues or organs at very low or freezing temperatures in order to save them for future use [1]. In practice, biological material is combined with cryoprotectants, cooled under a controlled protocol and held in liquid nitrogen or its vapour phase (about −196 °C). Freezing and thawing are not loss-free: a 2019 study of adipose-derived stromal vascular fraction (SVF) reported that cryopreservation reduced cell counts but not the stem cell potency of the surviving cells [4]. Storage conditions, documentation and donor consent are regulated in most countries [2].

Key Facts

Item	Detail
Entity	Cryopreservation (also: cell cryopreservation, cryobanking)
Definition	Cooling and storing cells, tissues or organs at very low or freezing temperatures to save them for future use [1]
Typical storage medium	Liquid nitrogen, liquid or vapour phase (approximately −196 °C)
Key additives	Cryoprotective agents (CPAs), for example dimethyl sulfoxide (DMSO) or glycerol, usually with a protein or serum carrier
Main technical challenge	Ice-crystal formation, osmotic stress and cryoinjury during freezing and thawing
Reported effect on adipose SVF	Reduced cell counts after cryopreservation; stem cell potency of surviving cells retained in the cited study [4]
Evidence synthesis	A 2026 systematic review examined the effects of cryopreservation on SVF viability in human adipose tissue [5]
Governance	Consent, documentation, traceability and quality standards apply to banked human cells; professional guidance is published by the International Society for Stem Cell Research (ISSCR) [2]
Typical post-thaw recovery rates by cell type	source pending

Definition

Cryopreservation is defined by the National Cancer Institute as the process of cooling and storing cells, tissues or organs at very low or freezing temperatures so that they can be saved for future use [1]. The term covers both the preservation step itself and the wider workflow that surrounds it: collection, processing, addition of cryoprotectants, controlled cooling, long-term storage, thawing and quality control before the material is used.

Cryopreservation is a storage method, not a treatment. It does not change what a cell can do; it aims to hold biological material in a metabolically inactive state until it is needed. Whether a cryopreserved cell product is appropriate for a given clinical use depends entirely on the underlying indication and the evidence for that specific application [2].

Medical and Scientific Background

At physiological temperatures, cells continuously consume energy and degrade. Lowering the temperature slows metabolism; below roughly −130 °C, water no longer supports molecular mobility sufficient for biochemical reactions, so biological time is effectively arrested. Liquid nitrogen storage at about −196 °C is therefore the conventional reference standard for long-term banking of cells [1].

Cryoinjury

The damage that limits cryopreservation occurs mainly during cooling and warming rather than during steady-state storage. Two classical mechanisms are described:

Intracellular ice formation. If cooling is too fast, water inside the cell freezes and ice crystals disrupt membranes and organelles.
Solution effects (osmotic injury). If cooling is too slow, extracellular ice concentrates the remaining solutes, cells dehydrate excessively and are exposed to high salt concentrations for prolonged periods.

Optimal protocols therefore balance these opposing risks, which is why the ideal cooling rate differs between cell types.

Cryoprotectants

Cryoprotective agents reduce ice-crystal formation and moderate osmotic stress. Permeating agents such as dimethyl sulfoxide (DMSO) and glycerol enter the cell and lower the amount of ice formed; non-permeating agents such as sugars and macromolecules act mainly in the extracellular space. Cryoprotectants are themselves potentially toxic to cells at higher concentrations and temperatures, so exposure time, temperature and concentration are controlled, and in many protocols the agent is removed or diluted after thawing.

Slow freezing versus vitrification

Two broad strategies are used. Controlled-rate (slow) freezing cools the sample at a defined rate with moderate cryoprotectant concentrations and is widely used for cell suspensions. Vitrification uses very high cryoprotectant concentrations and extremely rapid cooling so that the sample solidifies into a glass-like state without ice crystals; it is particularly relevant for structured tissues and some reproductive cells.

How It Works

Collection and consent. Human cells or tissue are obtained under documented informed consent, with donor screening and traceability records [2].
Processing. The sample is isolated or enriched as required — for example, mechanical or enzymatic processing of adipose tissue to obtain the stromal vascular fraction [4].
Formulation. Cells are suspended in a freezing medium containing a cryoprotectant and a carrier protein, then aliquoted into labelled cryovials or freezing bags.
Controlled cooling. The sample is cooled using a controlled-rate freezer or a passive cooling device, typically down to around −80 °C before transfer.
Long-term storage. Containers are transferred to liquid nitrogen (liquid or vapour phase) at approximately −196 °C, with inventory records, temperature monitoring and alarm systems.
Thawing. Rapid warming, usually in a temperature-controlled water bath or dry warming device, limits the time spent in the temperature range where ice recrystallises.
Post-thaw handling. The cryoprotectant is diluted or washed out, and viability, cell count, sterility and identity are assessed before release or use.

Post-thaw quality control matters because the number of recoverable cells after freezing and thawing is typically lower than before cryopreservation [4][5].

Applications

Clinical cell therapy and transplantation

Cryopreservation allows cell grafts to be collected, tested and released on a schedule independent of the procedure date. It is integral to established fields such as haematopoietic cell transplantation and to the logistics of manufactured cell products. Any clinical use of stem cell–based products should be matched to indications supported by clinical evidence and appropriate oversight [2][3].

Adipose-derived cells and the stromal vascular fraction

Adipose tissue can be processed to yield the stromal vascular fraction, a heterogeneous cell population that includes adipose-derived stromal/stem cells. Cryopreservation has been investigated as a way to store SVF for later use rather than requiring a fresh harvest for each procedure. Published work reports that cryopreservation reduces SVF cell counts while the stem cell potency of the surviving cells is retained [4], and a 2026 systematic review has examined the effects of cryopreservation on SVF viability in human adipose tissue [5].

Reproductive medicine and fertility preservation

Cryopreservation is used to store gametes, embryos and reproductive tissue, including for patients facing treatments that may impair fertility [1].

Biobanking and research

Research relies on frozen cell lines, primary cells, induced pluripotent stem cells and tissue banks to enable reproducible experiments, distribution between laboratories and long-term follow-up studies. Banked human biological material used in stem cell research is subject to consent, provenance and governance requirements [2].

Potential Benefits

Time separation. Collection and use can be separated by days, months or years, which supports scheduling, transport and multi-dose treatment plans [1].
Quality control before use. Freezing creates a window in which sterility, identity and potency testing can be completed before release.
Fewer repeat harvests. A single donation can be divided into multiple aliquots, potentially avoiding repeated invasive collection procedures.
Reproducibility in research. Frozen reference banks allow the same starting material to be used across experiments and laboratories.
Fertility and future-use preservation. Material can be stored before interventions that may compromise the tissue of origin [1].

Limitations

Cell loss. Freezing and thawing reduce the number of surviving cells; in adipose SVF this has been documented as a reduction in cell counts after cryopreservation [4].
Protocol dependence. Outcomes vary with cryoprotectant type and concentration, cooling and warming rates, storage temperature, container type and post-thaw washing; the systematic review literature reflects this heterogeneity across studies [5].
Cell-type specificity. A protocol validated for one cell type does not automatically transfer to another; structured tissues are generally harder to preserve than single-cell suspensions.
Functional endpoints differ from viability. Membrane-integrity viability assays may overstate functional recovery; potency, differentiation and proliferation endpoints are needed to characterise a product [4].
Infrastructure and cost. Long-term storage requires continuous nitrogen supply, monitoring, redundancy and documentation. Specific storage costs and durations: source pending.
Storage duration limits. Maximum evidence-based storage durations for specific cell products: source pending.

Risks and Safety

Product-related risks

Reduced cell dose. Because cell counts fall after thawing, the delivered dose may be lower than the collected dose unless this is accounted for [4].
Cryoprotectant exposure. Residual DMSO in infused products is associated with infusion-related reactions in transplant medicine; protocols therefore limit the volume and concentration administered. Quantitative thresholds: source pending.
Microbial contamination. Contamination can be introduced during processing or handling; sterility testing before release is standard practice.
Cross-contamination and container failure. Storage in the liquid phase of nitrogen has been associated with a theoretical risk of cross-contamination between containers, which is one reason vapour-phase storage and sealed containers are used.
Storage and identity failures. Equipment failure, nitrogen supply interruption or labelling errors can lead to loss or mix-up of irreplaceable samples; monitoring, alarms and chain-of-custody documentation are core safeguards [2].

Clinical and ethical safeguards

Cryopreservation is sometimes marketed as part of stem cell offerings whose clinical benefit has not been demonstrated. Patients are advised to check whether a proposed treatment is supported by published evidence, is subject to regulatory oversight and is delivered with transparent consent and follow-up [3]. Professional guidance sets expectations for consent, provenance, oversight and responsible communication in stem cell research and clinical translation [2].

Who May and May Not Be Suitable

May be considered

People undergoing procedures in which cells or tissue are collected for a documented later clinical or research purpose.
Patients for whom timing, transport or batch testing requires storage between collection and use.
Individuals preserving reproductive material before interventions that may affect fertility [1].
Research and biobanking contexts requiring reproducible, traceable starting material [2].

May not be suitable or requires caution

Situations where the intended downstream use is itself unproven, since storage does not create clinical benefit [3].
Applications requiring a high cell dose where post-thaw losses cannot be offset by collecting more material [4].
Cell or tissue types for which no validated cryopreservation protocol exists.
Known hypersensitivity or contraindication to components of the freezing medium, including DMSO, in products intended for infusion.
Settings without documented consent, traceability, monitored storage and quality control [2].

Evidence

The definitional basis for cryopreservation is well established in standard medical terminology [1]. For adipose-derived cells specifically, a 2019 study published in Plastic and Reconstructive Surgery – Global Open reported that cryopreservation of stromal vascular fraction cells reduced their counts but not their stem cell potency [4]. A 2026 systematic review in Tissue Engineering and Regenerative Medicine examined the effects of cryopreservation on stromal vascular fraction viability in human adipose tissue, synthesising results across studies [5]. Exact pooled viability figures, effect sizes and the number of included studies: source pending.

Interpretation caveats: much of the available literature is laboratory-based and measures viability, cell counts and in-vitro potency rather than patient-relevant clinical outcomes. Protocols differ substantially between studies, limiting direct comparison [5]. Evidence that a cryopreserved cell product improves clinical outcomes must come from clinical trials for the specific indication concerned [2].

Comparison: Fresh Versus Cryopreserved Cells

This page is a general entity page rather than a head-to-head comparison, but the practical trade-off most often raised is between using freshly isolated cells and using cryopreserved cells.

Aspect	Freshly isolated cells	Cryopreserved cells
Cell recovery	No freeze–thaw loss	Cell counts reduced after thawing in reported SVF data [4]
Reported potency of surviving cells	Baseline reference	Stem cell potency of surviving SVF cells retained in the cited study [4]
Scheduling	Collection and use must be closely linked	Collection and use can be separated in time [1]
Pre-release testing	Limited time for sterility and potency testing	Testing can be completed before release
Repeat procedures	New harvest needed for each use	Multiple aliquots from one donation
Infrastructure	Processing capability only	Controlled-rate freezing, monitored nitrogen storage, inventory systems
Protocol variability	Fewer variables	Outcome depends on cryoprotectant, cooling rate, storage and thaw method [5]

Regulation, Consent and Documentation

Handling and storage of human cells for clinical or research use is regulated in most jurisdictions. Core requirements typically include informed consent covering intended and future uses, donor screening, traceability from donor to recipient, defined storage conditions with monitoring, and defined release criteria. Professional guidance for stem cell research and clinical translation sets out expectations for consent, provenance, oversight and communication with patients [2], and patient-facing resources emphasise verifying oversight and evidence before agreeing to stem cell–related procedures [3]. Jurisdiction-specific rules, licence requirements and permitted storage periods: source pending.

Practical Summary

Cryopreservation is a mature enabling technology rather than a therapy. It reliably preserves biological material for future use [1], at the cost of some cell loss during freezing and thawing [4]. Its value in a given setting depends on the validity of the protocol used, the quality controls in place, the governance framework around consent and storage [2], and the strength of evidence for the downstream clinical application [3].